Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.

To evaluate the safety and efficacy of anagrelide when used to reduce platelet counts in patients with thrombocytosis.
Five hundred seventy-seven patients were treated with anagrelide to control the thrombocytosis of chronic myeloproliferative diseases. Three hundred thirty-five patients had primary thrombocythemia, 114 chronic granulocytic leukemia, 68 polycythemia vera, and 60 undifferentiated myeloproliferative diseases. Of the 577 patients, 504 were known to have been previously treated unsuccessfully with other modalities.
Of the 577 patients treated, 424 were evaluable for response. Anagrelide in doses of 0.5 mg to 1.0 mg four times a day reduced the platelet count by 50%, or to less than 600,000/mm3, for at least 28 days in 396 of the 424 (93%) evaluable patients. Acquired resistance to the drug was not observed. Major side effects were neurologic, gastrointestinal, and cardiac. In more than 5 years, 16% of patients discontinued treatment because of side effects.
Our experience suggests that anagrelide should become a useful agent in controlling the thrombocythemia seen in chronic myeloproliferative diseases and can be effective in patients in whom treatment with currently available agents has failed.
JournalThe American journal of medicine (Am J Med) Vol. 92 Issue 1 Pg. 69-76 (Jan 1992) ISSN: 0002-9343 [Print] UNITED STATES
PMID1731512 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Platelet Aggregation Inhibitors
  • Quinazolines
  • anagrelide
  • Hydroxyurea
  • Aged
  • Clinical Protocols
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydroxyurea (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors (adverse effects, therapeutic use)
  • Platelet Count
  • Quinazolines (administration & dosage, adverse effects, therapeutic use)
  • Thrombocytosis (blood, drug therapy, mortality)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: